Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVEKEO vs METHYLPHENIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
Treatment of acute cyanide poisoning,Off-label: Prevention of cyanide toxicity from sodium nitroprusside infusion
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
Sodium nitrite is metabolized primarily to methemoglobin and nitric oxide. Sodium thiosulfate is metabolized to thiocyanate by rhodanese.
Methylphenidate is primarily metabolized via deesterification to ritalinic acid (inactive) by carboxylesterase enzymes (CES1A1 in the liver). Minor metabolism occurs via hydroxylation, oxidation, and conjugation.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
40-50% bound to serum albumin and α1-acid glycoprotein.
~30% (primarily to albumin)
0.6-0.8 L/kg. Clinical meaning: Moderate distribution suggests limited tissue penetration; primarily confined to extracellular fluid.
13–28 L/kg (high due to extensive tissue distribution)
Oral: 85-95%. Rectal: 70-80%. Intramuscular: 90-100%.
Oral immediate-release: 10–20% (extensive first-pass metabolism); Extended-release: comparable to IR. Transdermal: ~50–60% of total dose.
No adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR 30-89 m L/min: No adjustment recommended. GFR <30 m L/min: Use with caution; reduce dose by 50% due to potential accumulation. Hemodialysis: Not recommended.
No adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate or severe hepatic impairment (Child-Pugh B or C) due to limited data.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Not approved for pediatric patients; safety and efficacy not established.
Weight-based: 0.3-0.6 mg/kg/dose up to 0.8 mg/kg/day. Immediate-release: 2.5-5 mg twice daily initially; titrate by 2.5-5 mg weekly; maximum 60 mg/day. Extended-release (age ≥6): 18 mg once daily; titrate by 18 mg weekly; maximum 54 mg/day.
No specific dose adjustment recommended; clinical studies included patients ≥65 years with no overall differences in safety or efficacy.
Start at 2.5 mg twice daily; titrate slowly by 2.5-5 mg every 2-3 weeks; maximum 40 mg/day. Monitor for cardiovascular effects, anxiety, and insomnia.
Risk of severe hypotension and methemoglobinemia. Monitor methemoglobin levels. Use caution in patients with low oxygen saturation.
Methylphenidate has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Carefully consider the risks of abuse before prescribing, and monitor for signs of abuse and dependence during therapy.
Can cause severe hypotension requiring vasopressors,Methemoglobinemia may reduce oxygen delivery; avoid in patients with significant anemia or G6PD deficiency,Thiocyanate accumulation with prolonged use, especially in renal impairment
Serious cardiovascular events including sudden death in patients with pre-existing cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events such as psychosis or mania,Suppression of growth in children,Seizures,Priapism,Peripheral vasculopathy including Raynaud's phenomenon,Drug dependence and withdrawal upon abrupt discontinuation
Hypersensitivity to sodium nitrite or sodium thiosulfate,Methemoglobin reductase deficiency
Hypersensitivity to methylphenidate or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Motor tics or a family history or diagnosis of Tourette's syndrome,Severe anxiety, tension, agitation,Pre-existing structural cardiac abnormalities or serious heart arrhythmias
No known food interactions. EVEKEO is administered intravenously and is not affected by oral intake. However, in neonates, careful monitoring of electrolyte and fluid balance is important.
Avoid high-fat meals near dosing of extended-release formulations as they may delay absorption or alter drug release. Generally, methylphenidate can be taken with or without food, but consistency is advised. Acidic foods (e.g., citrus fruits, cola) may decrease absorption; separate by at least 1 hour.
Pregnancy Category N (not assigned). No adequate human data; based on animal studies, fetal harm is possible. Avoid use in first trimester if alternative available. Risk in second and third trimesters unknown.
First trimester: Limited data; possible increased risk of congenital heart defects. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties).
No data on excretion in human milk. M/P ratio unknown. Caution if breastfeeding; consider risk vs benefit.
M/P ratio: 2.4. Excreted in breast milk; potential for infant agitation and insomnia. Avoid breastfeeding or use with caution, monitoring infant for adverse effects.
No pharmacokinetic studies in pregnancy; dose adjustment recommendations not established. Use lowest effective dose and shortest duration.
Pharmacokinetic changes: Increased clearance (up to 50%) and volume of distribution in late pregnancy, potentially requiring dose increases to maintain efficacy. Individualize based on clinical response and tolerability; postpartum dose may need reduction.
EVEKEO is a beta-adrenergic agonist indicated for the treatment of bradycardia in premature neonates. It is given intravenously and has a rapid onset of action (1-2 minutes). Monitor heart rate and blood pressure continuously during infusion. Use with caution in patients with hyperthyroidism, diabetes, or history of seizures. Tachyphylaxis may develop with prolonged use.
Methylphenidate is a first-line stimulant for ADHD and narcolepsy. Immediate-release formulations have a short duration (3-4 hours); extended-release formulations provide coverage for 8-12 hours. Monitor for appetite suppression, insomnia, and growth in children. Use with caution in patients with hypertension, seizures, or tic disorders. Avoid concomitant use with MAOIs.
This medication is for hospital use only and will be given by a healthcare professional.,It is used to increase your baby's heart rate and improve blood flow.,The dose may be adjusted based on your baby's response and heart rate.,Potential side effects include increased heart rate, high blood pressure, or arrhythmias.,Report any signs of allergic reaction, such as rash or difficulty breathing, immediately.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow extended-release capsules/tablets whole; do not crush or chew.,Take last dose of immediate-release at least 6 hours before bedtime to avoid insomnia.,Avoid alcohol while taking methylphenidate.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Inform your doctor if you have a history of heart problems, high blood pressure, or seizures.,Report any new or worsening psychiatric symptoms (e.g., agitation, hallucinations).,Store at room temperature away from moisture and heat.
No interactions on record
"Bepridil, a calcium channel blocker with antianginal and class I/IV antiarrhythmic properties, may reduce the antihypertensive efficacy of methylphenidate by attenuating its central sympathomimetic effects. Methylphenidate, a CNS stimulant, typically increases blood pressure via enhanced norepinephrine and dopamine activity, but bepridil's calcium channel blockade in vascular smooth muscle and potential negative chronotropic effects can counteract these pressor responses, leading to diminished blood pressure control. This interaction is particularly relevant in patients using methylphenidate for ADHD or narcolepsy who have comorbid hypertension managed with bepridil, potentially resulting in elevated blood pressure readings and reduced therapeutic benefit."
"Methylphenidate is a moderate inhibitor of CYP2D6, the primary enzyme responsible for the metabolism of delavirdine. Co-administration can lead to elevated delavirdine plasma concentrations, increasing the risk of QT prolongation, hepatotoxicity, and other dose-related toxicities. Clinically, this may manifest as arrhythmias, elevated liver enzymes, or severe rash."
"Lofexidine, a centrally acting alpha-2 adrenergic agonist, reduces sympathetic outflow leading to decreased blood pressure. Methylphenidate, a central nervous system stimulant, can elevate blood pressure via sympathomimetic effects. When co-administered, lofexidine may partially antagonize the pressor effects of methylphenidate, potentially reducing methylphenidate's efficacy in managing attention deficit hyperactivity disorder. Clinically, this interaction may result in insufficient blood pressure control or attenuated therapeutic response to methylphenidate."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVEKEO vs METHYLPHENIDATE, answered by our medical review team.
EVEKEO is a CNS Stimulant that works by EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.. METHYLPHENIDATE is a CNS Stimulant that works by Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVEKEO and METHYLPHENIDATE depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVEKEO is: 5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.. The standard adult dose of METHYLPHENIDATE is: Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVEKEO and METHYLPHENIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVEKEO is classified as Category C. Pregnancy Category N (not assigned). No adequate human data; based on animal studies, fetal harm is possible. Avoid use in first trimester if alternative available. Risk in second . METHYLPHENIDATE is classified as Category A/B. First trimester: Limited data; possible increased risk of congenital heart defects. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal sy. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.